文献速递胸部肿瘤

挑战难治性疾病:小细胞肺癌分子驱动治疗的进展

Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2019-08-21

小细胞肺癌(SCLC)生存极差、数十年治疗进展有限,但近期药物开发带来新机遇。本综述探讨SCLC基因组特征,重点分析Notch通路与DLL3靶点、MYC与亚型转化、Bcl-2靶向药物,并指出免疫治疗(PD-L1/PD-1抑制剂单药及联合化疗)是近年唯一获批的进展,未来需生物标志物驱动和早期筛查。

要点

  • DLL3、MYC、Bcl-2为SCLC潜在分子靶点,但开发进度落后于免疫治疗
  • PD-L1/PD-1抑制剂单药及联合化疗是近年唯一获批的SCLC治疗
  • 生物标志物驱动开发依赖早期患者筛选和循环生物标志物

核心结论

  • SCLC曾被视为难治性疾病,但近期药物开发已打开潜在治疗途径,可能迎来进步时代。

研究设计与样本

  • 综述,探讨SCLC基因组景观及Notch通路、DLL3、MYC、Bcl-2等靶点,并回顾免疫治疗进展。

主要发现

  • Notch通路和DLL3是靶向尝试的关键节点,MYC对SCLC亚型转化具主要重要性。
  • Bcl-2在SCLC中高表达且可成药,相关靶向药物已综述。
  • PD-L1/PD-1抑制剂单药及联合化疗是近年唯一获批的SCLC治疗。

临床怎么用

  • SCLC药物开发需采用生物标志物驱动方法,依赖早期患者筛选和循环生物标志物。
  • 临床恶化迅速常妨碍患者入组试验,需关注早期识别和试验转介。

局限性

  • DLL3、MYC、Bcl-2等靶点药物开发进度尚不及免疫治疗领域。
  • SCLC快速临床恶化常阻碍患者进入临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small cell lung cancer (SCLC) has been described as a 'recalcitrant' disease characterised by poor survival and with little progress made in developing novel treatments in the last decades. However, recent drug developments have opened some potential therapeutic avenues. In this review, the genomic landscape of SCLC is explored, in particular the Notch pathway and attempts to target the key node DLL3. The likely primary importance of MYC to SCLC subtype transformation and recent attempts to drug MYC are discussed. Bcl-2 is a druggable protein, highly expressed in SCLC, and relevant Bcl-2 targeting drugs are reviewed. None of these drug targets are, however, as advanced their development as the field of immunotherapy for SCLC. The key developments in single agent PD-L1 and PD-1 inhibitors and in combination with chemotherapy have led to the only recent licencing approvals for SCLC in recent years and will likely pave the way for future rational drug combinations. Drug development in SCLC poses its own challenges with rapid clinical deterioration often precluding trial entry. Effective drug development in a biomarker-driven approach depends on early patient screening and use of circulating biomarkers. Given recent developments, we may hope to be at the start of an era of greater progress in the treatment of SCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mak DWS, Li S, Minchom A, et al. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer. Eur J Cancer. 2019. PMID: 31445197. doi:10.1016/j.ejca.2019.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。